H.C. Wainwright raised the firm’s price target on Delcath Systems (DCTH) to $29 from $24 and keeps a Buy rating on the shares after the company announced its intention to enter into a Medicaid National Drug Rebate agreement. This strategic move is prudent given that it could not only aid in accessing a larger patient base but also help in achieving sustainable growth, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DCTH:
- Delcath Systems Announces 2025 Financial Guidance
- Delcath Systems sees FY25 revenue $94M-$98M, consensus $94.47M
- Delcath Systems to enter Medicaid National Drug Rebate Agreement
- Delcath Systems Shareholders Approve Key Amendments at Meeting
- Delcath Systems: Strong Revenue Growth and Strategic Expansion Drive Buy Rating